Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Blood Sugar Take Care and Glucose Metabolism

11. marts 2013 opdateret af: NewChapter, Inc.

Effect of Blood Sugar Take Care on Glucose Metabolism, Determinants of Metabolic Syndrome, and Quality of Life in Prediabetic Adults: A Randomized, Double-blind, Placebo-controlled Study

This prospective international clinical trial is a two-arm, double-blind, randomized, placebo-controlled, parallel-group, multicenter study. 112 prediabetic subjects will be randomized to Blood Sugar Take Care or placebo. Randomization will be stratified by gender. The intervention period is 12 weeks. The primary outcome is fasting glucose levels.

Studieoversigt

Status

Trukket tilbage

Betingelser

Undersøgelsestype

Interventionel

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • San Francisco, California, Forenede Stater, 94109
        • SPRIM

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

SUBJECT INCLUSION CRITERIA: STEP 1

  1. Age ≥ 18 years
  2. Subject meets American Diabetes Association criteria for diabetes testing in asymptomatic, undiagnosed individuals:

    1. If age ≥45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia
    2. If age <45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia AND present with at least one of the following risk factors:

      • Have a first-degree relative with diabetes
      • Habitually physically inactive
      • Race is African-American, Hispanic American, Native American, Asian American, or Pacific Islander
      • Have delivered a baby weighing >9 lb or have been diagnosed with gestational diabetes mellitus
      • Hypertensive (≥140/90)
      • Known HDL cholesterol level 35 mg/dl
      • Known triglyceride level ≥250 mg/dl
      • On previous testing, had impaired glucose tolerance or impaired fasting glucose
      • History of vascular disease
  3. Stable body weight (<5% change) in the last 3 months
  4. Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (females only)
  5. Able to understand the nature and purpose of the study including potential risks and side effects
  6. Willing to consent to study participation and to comply with study requirements

SUBJECT EXCLUSION CRITERIA

  1. Known diabetes (type I or II)
  2. Recent use (within 2 weeks of screening) of any dietary supplement including vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal ingredient/product that significantly affects glucose or lipid metabolism
  3. Recent use (within 4 weeks of screening) of any prescription or OTC medication that significantly affects glucose or lipid metabolism, including but not limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, systemic corticosteroids, statins, fibrates, niacin, and bile acid sequestrants
  4. Daily use of nonsteroidal anti-inflammatory drugs (NSAIDS); (daily baby aspirin use acceptable)
  5. Any comorbidity that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
  6. Anticipated changes in dietary patterns or physical activity levels during the study, including attempts at body weight reduction
  7. Eating disorder
  8. Polycystic ovary syndrome
  9. Known allergies to any substance in the study product
  10. Pregnant or breastfeeding women
  11. History of alcohol, drug, or medication abuse
  12. Participation in another study with any investigational product within 3 months of screening
  13. Recent (<3 months) gastrointestinal surgery or any planned surgery during the treatment period

SUBJECT INCLUSION CRITERIA: STEP 2

1. Fasting glucose between 95 and 130 mg/dl, based on portable glucometer reading

SUBJECT INCLUSION CRITERIA: STEP 3

  1. Impaired fasting glucose, based on the American Diabetes Association definition of fasting serum glucose between 100 and 125 mg/dl
  2. Impaired glucose tolerance, based on the American Diabetes Association definition of serum glucose between 140 and 199 mg/dl 2 hours after a 75 g glucose load

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Multiherb product
Herbal product
One 1200 mg soft gel capsule administered 3X/day for duration of study
Andre navne:
  • BSTC
Placebo komparator: Placebo
Maltodextrin control
One 1200 mg soft-gel capsule administered 3X/day for duration of study

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Fastende glukose
Tidsramme: 12 uger
12 uger

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Uønskede hændelser
Tidsramme: 12 uger
12 uger
Blodtryk
Tidsramme: 12 uger
12 uger
Insulinfølsomhedsindeks
Tidsramme: 12 uger
12 uger
Fastende insulin
Tidsramme: 12 uger
12 uger
Homeostasis Model Assessment of Insulin Resistance
Tidsramme: 12 weeks
12 weeks
Quantitative insulin sensitivity check index
Tidsramme: 12 weeks
12 weeks
Insulin secretion/insulin resistance index
Tidsramme: 12 weeks
12 weeks
Glykosyleret hæmoglobin (HbA1c)
Tidsramme: 12 uger
12 uger
High-sensitivity C-reactive protein
Tidsramme: 12 weeks
12 weeks
High-molecular weight adiponectin
Tidsramme: 12 weeks
12 weeks
Lipids (total cholesterol, HDL, LDL, VLDL, triglycerides)
Tidsramme: 12 weeks
12 weeks
Body composition
Tidsramme: 12 weeks
height/weight, body mass index, waist circumference, hip circumference, waist-to-hip ratio
12 weeks
WHO Quality of Life Questionnaire
Tidsramme: 12 weeks
12 weeks
Comprehensive metabolic panel
Tidsramme: 12 weeks
12 weeks
Fuldstændig blodtælling
Tidsramme: 12 uger
12 uger
Gastrointestinal Symptom Rating Scale
Tidsramme: 12 weeks
12 weeks
Pulse
Tidsramme: 12 weeks
12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Larry Miller, PhD, Sprim Advanced Life Sciences

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. juni 2012

Primær færdiggørelse (Forventet)

1. oktober 2013

Studieafslutning (Forventet)

1. november 2013

Datoer for studieregistrering

Først indsendt

7. marts 2012

Først indsendt, der opfyldte QC-kriterier

13. marts 2012

Først opslået (Skøn)

14. marts 2012

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

12. marts 2013

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. marts 2013

Sidst verificeret

1. marts 2013

Mere information

Begreber relateret til denne undersøgelse

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Blood Sugar Take Care

Abonner